Official and authoritative background links used for intake education.
Evidence-informed medication review
Oxbryta use and medical records checklist
The FDA announced the voluntary market withdrawal of Oxbryta in September 2024 because of safety concerns. This intake path documents use, treatment timing, medical events, and follow-up care without promising legal eligibility.
Oxbryta Lawsuit Overview
People are filing lawsuits against Pfizer after experiencing severe complications from taking Oxbryta (voxelotor), a drug intended to treat sickle cell disease (SCD). On September 25, 2024, the drug was voluntarily withdrawn from global markets after data revealed it increased the risk of vaso-occlusive crises (VOCs) and death—conditions it was meant to prevent.
Lawsuits allege that the manufacturer failed to validly warn patients about these dangers. Injured patients and families are now seeking compensation for medical costs, pain and suffering, and wrongful death associated with the drug.
What Is Oxbryta?
Oxbryta (voxelotor) was a prescription medication capable of treating sickle cell disease (SCD) by inhibiting hemoglobin S polymerization. It was designed to target the root cause of sickling cells to prevent complications. However, post-marketing studies showed that instead of helping, widespread use was associated with worse outcomes, including higher rates of VOCs and mortality.
Global Withdrawal: On September 25, 2024, Pfizer announced the voluntary withdrawal of all lots of Oxbryta worldwide and suspended all clinical trials due to safety concerns.
Serious Side Effects & Risks
While common side effects included headache, fever, and rash, the lawsuit focuses on severe, life-threatening complications that were not adequately warned against.
Critical Complications
Vaso-Occlusive Crises (VOCs): Severe pain episodes caused by blocked blood flow.
Stroke: A life-threatening event caused by disrupted blood supply to the brain.
Organ Damage: Specifically affecting the kidneys and liver secondary to VOCs.
Pediatric Deaths: Higher rates of mortality observed in children in registry-based studies.
Other Vascular Events
Blood Clots: Increased risk of serious vascular events.
Severe Allergic Reactions: Anaphylaxis, swelling, and difficulty breathing.
Acute Chest Syndrome: Often associated with severe VOCs.
Eligibility Criteria
If you or a loved one suffered severe injury or death after taking Oxbryta, you may be entitled to significant compensation.
You typically qualify to file a claim if you:
Were prescribed Oxbryta for Sickle Cell Disease.
Experienced a Vaso-Occlusive Crisis (VOC), Stroke, or Organ Damage during or after treatment.
Suffered from other serious vascular events or blood clots.
Are a surviving family member of a patient who died due to complications linked to Oxbryta.
Oxbryta Lawsuit FAQs
On September 25, 2024, Pfizer voluntarily withdrawn Oxbryta globally after post-market clinical trials indicated that the risks of the drug—specifically an increased incidence of vaso-occlusive crises (VOCs) and fatal events—outweighed its benefits.
Oxbryta has been linked to severe complications including increased vaso-occlusive crises (VOCs), blood clots, serious vascular events, organ damage (kidney/liver), stroke, and pediatric deaths. These are in addition to common side effects like headache, diarrhea, and rash.
You may be eligible if you were prescribed Oxbryta for Sickle Cell Disease and experienced a vaso-occlusive crisis (VOC), organ damage, stroke, or other severe complications during or after treatment. Surviving family members of patients who passed away due to these complications may also file a wrongful death claim.
Settlements vary based on the severity of injuries and circumstances. Estimated ranges for moderate cases (non-fatal VOCs) are $50,000–$200,000, while severe cases or wrongful death claims could range from $500,000 to $1.5 million or more. There is no guaranteed amount.
Private case review
Oxbryta Lawsuit
Answer the questions below. Your submission is private and does not guarantee case acceptance.
Free to submitNo obligationConsent required before submission
Evidence-informed medication review
Campaign guidance, records, and sources
Review the supporting information below before or after completing the private campaign form.
A practical checklist to help organize useful details before review.
Reviewed for intake accuracy by AMMS Compliance Team
Records and details that may help
- Oxbryta prescriptions and pharmacy records
- First and last use dates and dose history
- Sickle cell treatment and hospitalization records
- Records documenting the reported medical event and follow-up
Sources used for intake education
These official references are provided for background education only. They do not replace medical or legal advice.
- FDA Oxbryta withdrawal alertOfficial FDA safety communication about the voluntary market withdrawal.
1. Submit the intake form
Share your contact details and answer the existing campaign-specific questions.
2. Organize supporting details
Gather the records, dates, communications, and other details listed for this campaign.
3. Intake follow-up
AMMS or an authorized intake partner may contact you for missing or clarifying details.
4. Legal review if appropriate
Qualified legal professionals decide whether a claim can move forward. AMMS does not provide legal advice or guarantee results.
Frequently asked questions
What did the FDA say about Oxbryta?
The FDA announced in September 2024 that the manufacturer voluntarily withdrew Oxbryta from the market because of safety concerns.
Should a patient change treatment without medical advice?
No. Patients should discuss treatment changes with their healthcare professional.
Related AMMS resources
AMMS Legal Intake Research TeamReviewed for intake accuracy by AMMS Compliance TeamLast reviewed: 09/16/2026
Important: AMMS provides intake and educational information. We are not providing medical or legal advice on this page, and submitting a form does not create an attorney-client relationship. Case value, eligibility, filing deadlines, and legal strategy must be reviewed by qualified professionals.